NCT06084299View on ClinicalTrials.gov

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 27, 2020

Primary Completion Date

August 30, 2026

Study Completion Date

August 30, 2026

Conditions
Liver Cancer
Interventions
BIOLOGICAL

Autologous Tumor Infiltrating Lymphocytes

Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation, and extensive expansion.

Trial Locations (1)

430000

RECRUITING

Tongji Hospital, Wuhan

All Listed Sponsors
collaborator

Wuhan Elongevity Technology Co., Ltd.

UNKNOWN

lead

Zhiyong Huang

OTHER